Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021112207 - DRUG FOR TREATING SYMPTOM OF CEREBRAL INFARCTION IN ACUTE STAGE CEREBRAL INFARCTION PATIENT

Publication Number WO/2021/112207
Publication Date 10.06.2021
International Application No. PCT/JP2020/045158
International Filing Date 04.12.2020
IPC
A61K 38/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61P 7/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A61P 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
A61P 9/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 14/575 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
Applicants
  • 国立研究開発法人国立循環器病研究センター NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER [JP]/[JP]
  • 国立大学法人宮崎大学 UNIVERSITY OF MIYAZAKI [JP]/[JP]
Inventors
  • 猪原 匡史 IHARA Masafumi
  • 齊藤 聡 SAITO Satoshi
  • 吉本 武史 YOSHIMOTO Takeshi
  • 北村 和雄 KITAMURA Kazuo
  • 北 俊弘 KITA Toshihiro
Agents
  • 特許業務法人平木国際特許事務所 HIRAKI & ASSOCIATES
Priority Data
2019-22001505.12.2019JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) DRUG FOR TREATING SYMPTOM OF CEREBRAL INFARCTION IN ACUTE STAGE CEREBRAL INFARCTION PATIENT
(FR) MÉDICAMENT DE TRAITEMENT DES SYMPTÔMES DE L'INFARCTUS CÉRÉBRAL CHEZ UN PATIENT SOUFFRANT D'INFARCTUS CÉRÉBRAL AU STADE AIGU
(JA) 急性期脳梗塞患者における脳梗塞の症状を治療するための医薬
Abstract
(EN)
The present invention provides a means for treating a symptom of cerebral infarction in a cerebral infarction patient, particularly in an acute stage cerebral infarction patient, without causing undesirable side effects, by optimizing the administration and dosage of a drug that includes, as an active ingredient, adrenomedullin (AM) or a derivative thereof having adrenomedullin activity. One aspect of the present invention relates to a drug for treating a symptom of cerebral infarction in an acute stage cerebral infarction patient, said drug including, as an active ingredient, adrenomedullin or a derivative thereof having adrenomedullin activity, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of any of these.
(FR)
La présente invention concerne un moyen de traitement d'un symptôme d'infarctus cérébral chez un patient souffrant d'infarctus cérébral, particulièrement chez un patient souffrant d'infarctus cérébral au stade aigu, sans provoquer d'effets secondaires indésirables, en optimisant l'administration et le dosage d'un médicament qui comprend, comme ingrédient actif, de l'adrénomédulline (AM) ou son dérivé ayant une activité adrénomédulline. Un aspect de la présente invention concerne un médicament de traitement d'un symptôme d'un infarctus cérébral chez un patient souffrant d'infarctus cérébral au stade aigu, ledit médicament comprenant, comme ingrédient actif, de l'adrénomédulline ou son dérivé ayant une activité adrénomédulline, ou son sel pharmaceutiquement acceptable, ou un solvate pharmaceutiquement acceptable de n'importe lequel de ces derniers.
(JA)
本発明は、脳梗塞患者、特に急性期脳梗塞患者において、AM又はアドレノメデュリン活性を有するその誘導体を有効成分として含有する医薬の用法及び用量を最適化することにより、望ましくない副作用を生じることなく脳梗塞の症状を治療する手段を提供する。本発明の一態様は、アドレノメデュリン若しくはアドレノメデュリン活性を有するその誘導体、若しくはその製薬上許容される塩、又はそれらの製薬上許容される溶媒和物を有効成分として含有する、急性期脳梗塞患者における脳梗塞の症状を治療するための医薬に関する。
Latest bibliographic data on file with the International Bureau